Biomedical Engineering

Biotechnology company reports progress in avian transgenics biomanufacturing

Published in Genomics and Genetics Weekly, March 18th, 2005

Viragen, Inc. (VRA) announced an advancement in its program to develop avian transgenic biomanufacturing for the purpose of using chickens as bioreactors for the efficient and economical production of human pharmaceutical protein-based drugs in their eggs.

Viragen, in collaboration with Roslin Institute and Oxford Biomedica PLC, reported that an antibody designed to treat malignant melanoma (anti-GD3 antibody) has been successfully detected in the blood of a founder transgenic rooster after the antibody was introduced using a proprietary gene delivery system. This achievement is the first in a series of steps designed to confirm that a humanized antibody can be produced...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Genomics and Genetics Weekly

Source: Genomics and Genetics Weekly (2005-03-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry